Interaction of Volatile Anesthetics With Magnesium

• Status: Not yet recruiting
• Trial end date: 2024-03-15
• Target enrollment: 0
• Participant gender: All

Summary

Magnesium and volatiles anesthetics both have an effect on the neuromuscular transmission. The primary objective of the study is to quantify the effect of a perfusion of intravenous magnesium on neuromuscular transmission measured by acceleromyography with the TofScan device in patients undergoing general anesthesia with volatile anesthetics (desflurane, sevoflurane and isoflurane) as compared to intravenous anesthesia with propofol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Christoph Czarnetzki
• Collaborators: Centre Hospitalier du Centre du Valais; Ospedale Regionale di Lugano
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

• Patients, age 18 to 65 years inclusive

• American Society of Anesthesiology [ASA] status I or II

• Body mass index 19 - 30 kg/m2

• Patient scheduled for elective surgery lasting ≥ 60 minutes

• Patient is able to read and understand the information sheet and to sign and date the consent form.

• Negative urinary or serum pregnancy test (not applicable if status post hysterectomy or tubal ligation or menopausal woman)

Exclusion Criteria:

• Surgery with need for neuromuscular block

• Contraindication for general anesthesia with laryngeal mask airway, such as gastro-oesophageal reflux.

• Hypersensitivity or allergy to magnesium sulfate or propofol

• Contraindication to volatile anesthetics such as malignant hyperthermia

• Patients with neuromuscular disease

• Patients receiving medications known to influence neuromuscular function (for instance, aminoglycosides or phenytoine)

• Known electrolyte abnormalities (for instance, hypermagnesemia)

• Atrioventricular heart block

• Patients with magnesium treatment within 48 hours before start of study

• Liver insufficiency (bilirubine <1.5x, ALAT/ASAT<2.5x the upper limit of normal value)

• Renal insuffisancy (créatinine <1.5x upper limit of normal value, clearance<30ml/minute)

• Patient having participated in any clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial.

• Pregnant or breast-feeding women.